<< Back to News

System Formulary Update
Zolbetuximab-clzb (Vyloy)
January 27, 2025

Situation: Zolbetuximab-clzb (Vyloy) was approved for addition to the UNC Health System Formulary at the System Pharmacy and Therapeutics Committee meeting.

Background: The following medication was reviewed: Zolbetuximab-clzb (Vyloy) 100 mg SDV for injection

Assessment/Recommendation: System P&T voted to include the following product to the UNC Health Medication Formulary with restrictions

• Zolbetuximab-clzb (Vyloy) 100 mg SDV for injection 

Restricted to patients in outpatient encounters or clinic use only who meet the following criteria:

• Adult patients with advanced, unresectable, or metastatic HER2 negative and CLDN18.2 positive gastric or GEJ adenocarcinoma

• Orders must be signed by a Hematology/Oncology Attending Physician

Formulary/Epic Changes will Go-Live on Tuesday, March 4^th